Alunbrig (brigatinib) 180 mg film-coated tablets, 28 tablets — original (Penn Pharmaceutical, United Kingdom) Lung cancer. Targeted cancer therapy. Delivery of medications from Europe within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Alunbrig is indicated as a monotherapy for the treatment of adult patients with advanced non-ligamentous lung cancer (ALCLC), positive for anaplastic lymphoma kinase (ALK), who have not previously received treatment. inhibitor ALK.

Alunbrig is indicated as monotherapy for the treatment of adult patients with advanced ALK-positive NCCLC who have previously been treated with crizotinib.

Dozi

The recommended dose of Alunbrig^®is 90 mg once per dose for the first 7 days followed by a further dose of 180 mg once per dose.

The stagnation of Alunbrig^® is interrupted for 14 days or more For other reasons, less likely to cause adverse reactions, restart treatment at a dose of 90 mg once daily for 7 days before increasing the dose to what was previously well tolerated.